These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8021334)

  • 1. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis.
    Cooney GF; Lum BL; Tomaselli M; Fiel SB
    J Clin Pharmacol; 1994 Mar; 34(3):255-9. PubMed ID: 8021334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
    Geller DE; Pitlick WH; Nardella PA; Tracewell WG; Ramsey BW
    Chest; 2002 Jul; 122(1):219-26. PubMed ID: 12114362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of aerosolized tobramycin in cystic fibrosis.
    Pai VB; Nahata MC
    Pediatr Pulmonol; 2001 Oct; 32(4):314-27. PubMed ID: 11568993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can tobramycin inhalation be improved with a jet nebulizer?
    Le Brun PP; Vinks AA; Touw DJ; Hekelaar N; Mannes GP; Brimicombe RW; Frijlink EH; Heijerman HG
    Ther Drug Monit; 1999 Dec; 21(6):618-24. PubMed ID: 10604822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
    Wang X; Koehne-Voss S; Anumolu SS; Yu J
    J Pharm Sci; 2017 Nov; 106(11):3402-3409. PubMed ID: 28634121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis.
    Touw DJ; Jacobs FA; Brimicombe RW; Heijerman HG; Bakker W; Briemer DD
    Antimicrob Agents Chemother; 1997 Jan; 41(1):184-7. PubMed ID: 8980777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
    Stenbit AE; Bullington WM; Heh JL; Flume PA
    J Cyst Fibros; 2013 Jul; 12(4):403-6. PubMed ID: 23266092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.
    Eisenberg J; Pepe M; Williams-Warren J; Vasiliev M; Montgomery AB; Smith AL; Ramsey BW
    Chest; 1997 Apr; 111(4):955-62. PubMed ID: 9106575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
    Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
    J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
    Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
    Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
    Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
    J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
    Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
    Geller DE; Rosenfeld M; Waltz DA; Wilmott RW;
    Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of aerosolized antibiotics in cystic fibrosis patients.
    Moss RB
    Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin.
    Vecellio L; Abdelrahim ME; Montharu J; Galle J; Diot P; Dubus JC
    J Cyst Fibros; 2011 Mar; 10(2):86-92. PubMed ID: 21075063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
    J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis.
    Mukhopadhyay S; Staddon GE; Eastman C; Palmer M; Davies ER; Carswell F
    Respir Med; 1994 Mar; 88(3):203-11. PubMed ID: 8209069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nebulizer configuration on delivery of aerosolized tobramycin.
    O'Riordan TG; Amram JC
    J Aerosol Med; 1997; 10(1):13-23. PubMed ID: 10166359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.